linjc16/ctgov huggingface dataset:
Electrohydraulic Versus Laser Lithotripsy for Treatment of Difficult to Remove Biliary Stones

Study Overview
=================
Brief Summary
-----------------
Bile duct stones that can't be removed by conventional means can often be removed after fragmentation by shock waves (lithotripsy). The shock waves that are used for fragmentation of these stones are generated by electric sparks (electrohydraulic lithotripsy) or laser (laser lithotripsy). Although both techniques have been used for many years, there are no studies comparing the efficacy of the two. The purpose of this study is to find out which technique is more effective.

Detailed Description
-----------------
Procedures will be considered standard of care; patients or insurance companies will be billed as it is standard of care.

Official Title
-----------------
Electrohydraulic Versus Laser Lithotripsy for Treatment of Difficult to Remove Biliary Stones

Conditions
-----------------
Gall Stones

Intervention / Treatment
-----------------
* Procedure: Laser Lithotripsy
* Procedure: Electrohydraulic Lithotripsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1 or more gall stones in bile duct which cannot be removed using conventional methods (must be fragmented) Adults able to provide informed consent Exclusion Criteria: Pregnancy or lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Electrohydraulic lithotripsy<br>Electrohydraulic lithotripsy: Lithotripsy will be performed using electrohydraulic method | Procedure: Electrohydraulic Lithotripsy<br>* Electrohydraulic Lithotripsy<br>|
| Experimental: Laser Lithotripsy<br>Laser Lithotripsy: Lithotripsy will be performed using laser method | Procedure: Laser Lithotripsy<br>* Laser Lithotripsy<br>* Other names: Lithotripsy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time | Identify which technique takes less time to completion. | Procudre duration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of shocks | Comparsion between procudures of the number of shocks to fragment stones | Procedure duration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biliary, lithotripsy, gall stones, bile duct, Biliary stones
Time to Perform Lung Function Test in Cystic Fibrosis

Study Overview
=================
Brief Summary
-----------------
Time to perform lung function test after chest physiotherapy in cystic fibrosis. The investigators study FEV1(forced expiratory volume in one second) and FVC (forced vital capacity).

Detailed Description
-----------------
The patients perform spirometry before, direct after, 30 minutes, 1 hour, 2 hours, and 3 hours after physiotherapist. The investigators want to study the FEV1 and FVC.

Official Title
-----------------
Time to Perform Lung Function Test in Cystic Fibrosis After Chest Physiotherapy.

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Procedure: Lung function test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with cystic fibrosis Exclusion Criteria: patients with cystic fibrosis who could not stay at the clinic for more than 4 hrs.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lung function test<br>Lung function test | Procedure: Lung function test<br>* Lung function test.<br>* Other names: Lung function test.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung function test. FEV1 and FVC |  | 2 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung function, Physiotherapy
Viatorr CX Case-control Study for Complications of Portal Hypertension

Study Overview
=================
Brief Summary
-----------------
To evaluate the clinical benefits in the patients receiving Viatorr CX over a period of 12 months of structured Follow-up (before TIPS, at TIPS, 1 week after TIPS, at 6 weeks, 4 months, 6 months, 9 months, 12 months), regarding clinical endpoints, such as HE, readmission, liver injury, cardiac function, response to TIPS and the passive expansion of the stents in real life.

Detailed Description
-----------------
Case-control study using the patients in the University Clinic Bonn receiving Viatorr CX (n=40), using a comparison ration 1:1:1 to Viatorr and bare metal stents. Of these patients, 20 patients will receive Viatorr CX and the assessement of the width of the stent as outlined in the JVIR-paper published this year. The Viatorr and BMS controls with similar age, gender, Child, MELD and indication for TIPS. A total of 125 patients with the primary composite-endpoint HE/readmission will be investigated Secondary endpoints are liver injury, cardiac function, response to TIPS and the passive expansion of the stents in real life.

Official Title
-----------------
Viatorr Control Expansion Compared to Bare-metal and Regular Viatorr for Complications of Portal Hypertension

Conditions
-----------------
Liver Cirrhoses, Portal Hypertension

Intervention / Treatment
-----------------
* Device: TIPS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients suitable for TIPS Exclusion Criteria: Contraindication for TIPS

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bare metal stent (BMS) TIPS<br>retrospective patients receiving BMS-TIPS for treatment of complications of portal hypertension. | Device: TIPS<br>* Transjugular Intrahepatic Portosystemic Shunt<br>|
| Regular Viatorr (RV) TIPS<br>retrospective patients receiving RV-TIPS for treatment of complications of portal hypertension. | Device: TIPS<br>* Transjugular Intrahepatic Portosystemic Shunt<br>|
| Viatorr Control Expansion (VCX)TIPS<br>prospective patients receiving VCX-TIPS for treatment of complications of portal hypertension. | Device: TIPS<br>* Transjugular Intrahepatic Portosystemic Shunt<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Readmissions | Number of readmissions will be documented using a structured CRF | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hepatic encephalopathy (HE) | Number of Episodes of overt HE (West Haven Criteria > Grad I) | 12 months | 
| Liver injury | Increase in liver function tests | 12 months | 
| Response to TIPS | grade of ascites after TIPS | 12 months |
Effect of Ketoconazole on the Pharmacokinetics of Vinflunine

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to test how ketoconazole affects with handling of vinflunine by the body which might affect how much vinflunine is in the blood stream and for how long

Official Title
-----------------
Effect of Ketoconazole on the Pharmacokinetics of Intravenous (IV) Vinflunine in Patients With Advanced Cancer

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Drug: vinflunine + ketaconazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Advanced cancer excluding cancer within the blood, adequate kidney and liver function. Exclusion Criteria: Prior use of vinflunine, other active medical disorders, severe nerve damage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: vinflunine + ketaconazole<br>* vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the effect of ketoconazole on the pharmacokinetics of vinflunine in patient with advanced cancer. A total of 28 blood samples will be collected |  | Days 1 through 5 and Day 8 of Cycles 1 and 2 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the safety of vinflunine co-administered with ketoconazole and assess the safety of vinflunine in patients with advanced cancer. Safety laboratory assessments and evaluations will be collected |  | weekly |
Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations

Study Overview
=================
Brief Summary
-----------------
Ischemia reperfusion injury causes the release of free oxygen radicals. The selective alpha2-receptor agonist, dexmedetomidine, has an inhibitory effect on inflammatory responses during ischemic injury. The aim of this study is to evaluate the effect of dexmedetomidine on inflammatory responses during ischemia-reperfusion injury in skeletal muscle.

Official Title
-----------------
Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Unilateral Total Knee Replacement - a Randomized, Controlled Trial

Conditions
-----------------
Arthroplasty, Replacement

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine
* Drug: normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society Anesthesiologists classification I-III Exclusion Criteria: use of antioxidants clinically significant cardiovascular, renal, or hepatic diseases heart block greater than the first degree

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control group<br>The control group received saline instead of dexmedetomidine. | Drug: normal saline<br>* The control group received the normal saline infusion<br>|
| Experimental: Dexmedetomidine group<br>The dexmedetomidine group received the dexmedetomidine. | Drug: Dexmedetomidine<br>* The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.<br>* Other names: precedex;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes of malondialdehyde (μmol/L) |  | up to 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes of interleukin-6 (pg/ml) |  | up to 1 day |
Mechanism and Prevention of Remote Organ Injury Following Ruptured Aortic Aneurysm

Study Overview
=================
Brief Summary
-----------------
It has been estimated that 80% of deaths from abdominal aortic aneurysms results from rupture. Endovascular Aneurysm Repair (EVAR) has been applied to RAAA (Ruptured Abdominal Aortic Aneurysm) patients with reports of improvements. Despite the use of EVAR, patients have developed complications with lung and kidney function. This study will investigate certain biochemical processes that will potentially reduce these complications. Knowledge gained from this study may also be used to further research in this field through larger studies.

Official Title
-----------------
Phase 1 Study of Complement Activation Following Ruptured Abdominal Aortic Aneurysm: Combining Human Observation With Animal Experimentation to Establish a Framework for Human Therapy

Conditions
-----------------
Abdominal Aortic Aneurysm

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Open/Elective EVAR patients Exclusion Criteria: Patients who do not present with abdominal aortic aneurysms or ruptured abdominal aortic aneurysm

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| multiple organ failure |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Open/Elective EVAR patients
Chronic Shoulder Pain Treated by Pressures With the Thumbs on the Trigger Points

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find the efficacy of treating the trigger points located around the shoulder in patients suffering from chronic shoulder pain.

Detailed Description
-----------------
Chronic shoulder pain is a common condition which should be treated by surgery only wen conservative approaches have been tried. in the present trial the authors intend to find the effectiveness of treating the triggers points located in muscles, ligaments and tendons surrounding the shoulderin patients suffering from chronic shoulder pain. The technique used in this trial is ischemic compression(thumb tip pressure) on the trigger points

Official Title
-----------------
Chronic Shoulder Pain of Myofascial Origin,a Randomised Clinical Trial Using Ischemic Compression Therapy.

Conditions
-----------------
Shoulder Pain

Intervention / Treatment
-----------------
* Procedure: ischemic compression


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 30 to 60 years old. To have suffered from shoulder pain on a daly basis for at least 3 months Participants had to be able to raise the arm above ther head. They had accept to receive 15 chiropractic treatments without charge. Exclusion Criteria: Past surgery to the arm. Injection to the shoulder in the month preceding the trial. A diagnosis of rheumatoid arthritis or any other systemic disorders affecting the joints. Shoulder pain from an herniated disc.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Ischemic compression on trigger points located around the shoulder. Active comparator. Ischemic compression, 5 weeks | Procedure: ischemic compression<br>* Active Comparator, ischemic compression, 3 times a week,5 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Shoulder Pain and Disability Index questionnaire |  | At baseline, after 15 treatments ,30 days aftr the treatments and 6 months later | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain visual analog scale |  | After 15 treatments, 30 days after the treatments and 6 months later. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chiropractic, myofascial trigger points, ischemic compression, shoulder pain
An Evaluation of Yoga Therapy for Cervical Spondylosis

Study Overview
=================
Brief Summary
-----------------
Cervical spondylosis is a chronic degenerative condition, commonly affecting >40-year-old adults worldwide. Cervical spondylosis is an important cause of neck pain and low back pain, and seriously affects the physical health, mental health, patients quality of life. Yoga has been most commonly used intervention for pain conditions. But its efficacy in cervical spondylosis has not yet been studied in clinical trials. The primary aim of the present study was to assess the efficacy of yoga chikitsa (therapy) compared with control intervention for neck pain caused by cervical spondylosis.

Official Title
-----------------
Effectiveness of Yoga Therapy for Neck Pain Relief in Patients With Cervical Spondylosis

Conditions
-----------------
Cervical Spondylosis, Neck Pain

Intervention / Treatment
-----------------
* Other: Yoga Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neck pain of CS as per diagnostic criteria of International Classification of Diseases CS supported by a physical examination, and cervical radiographic examination History of neck pain longer than 3 months willing to provide informed consent Exclusion Criteria: History of neck trauma, fracture or surgery, Systematic disease of the neck or spine including bones and joints conditions, Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Yoga Group<br>Experimental group received individualised yoga therapy twice a week for an hour for 12-weeks. | Other: Yoga Therapy<br>* An hour of yoga therapy included loosening exercise (sukshma vyayama), yoga postures (asana), yoga breathing (pranayama), relaxation (shavasana) and meditation. Each participant were given handouts to follow home practice sessions everyday for twice a day for at least 15 minutes.<br>|
| No Intervention: Control Group<br>Control group were given education session and continued on usual care for 12-weeks. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neck pain | ain intensity was measured by a 10-cm VAS scale, with 0 = no Pain and 10 = the worst imaginable pain | Change from baseline to 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disability | Neck disability was measured using neck disability index (NDI) score | Change from baseline to 12 weeks | 
| Health related Quality of Life | Short Form-36 assessed the Quality of life | change from baseline to 12 weeks |
The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Study Overview
=================
Brief Summary
-----------------
The diagnosis of Arrhythmogenic right ventricular cardiomyopathy can be difficult. The 80 lead ECG may increase the specificity and sensitivity in diagnosing this potentially life threatening inherited cardiac condition. This pilot would form the basis of a much larger clinical trial to test the utility of this novel diagnostic tool.

Official Title
-----------------
The Role of High Density Surface Cardiac Electrographic Mapping in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy :A Pilot Study

Conditions
-----------------
Arrhythmogenic Right Ventricular Cardiomyopathy

Intervention / Treatment
-----------------
* Device: 80 lead ECG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a confirmed diagnosis of arrhythmogenic right ventricular cardiomyopathy who are being followed up in the cardiology clinic Exclusion Criteria: Inability to consent Pacing dependent patients Other concomitant cardiag disease e.g. coronary artery disease Atrial fibrillation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patient<br>Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) | Device: 80 lead ECG<br> <br> |
| Other: Healthy volunteers<br>Aged and gender matched healthy controls. | Device: 80 lead ECG<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QRS wave dispersion in an ECG | The difference in QRS wave dispersion between the right and left ventricular leads | 5 minutes |